Literature DB >> 30179687

Histologic findings associated with false-positive multiparametric magnetic resonance imaging performed for prostate cancer detection.

Jennifer B Gordetsky1, David Ullman2, Luciana Schultz3, Kristin K Porter4, Maria Del Carmen Rodriguez Pena2, Carli E Calderone5, Jeffrey W Nix5, Michael Ullman6, Sejong Bae7, Soroush Rais-Bahrami8.   

Abstract

Magnetic resonance imaging (MRI)/ultrasound fusion-targeted biopsy (TB) has been shown to more accurately identify higher-grade prostate cancers compared with standard-of-care systematic sextant prostate biopsy (SB). However, occasional false-positive imaging findings occur. We investigated the histologic findings associated with false-positive prostate MRI findings. A retrospective review was performed on our surgical pathology database from 2014 to 2017 selecting patients with no cancer detected on TB with concurrent SB after at least 1 prior benign SB session. Histologic features evaluated included percentage of core involvement by chronic inflammation, percentage of core composed of stroma, percentage of glands involved by atrophy, and presence of the following features: acute or granulomatous inflammation, stromal nodular hyperplasia, adenosis, squamous metaplasia, basal cell hyperplasia, and presence of skeletal muscle. Histologic findings were compared between TB and concurrent SB. We identified 544 patients who underwent TB. Of these, 41 patients, including 62 targeted lesions, met criteria. Compared with SB tissue, the mean percentage of stroma was increased in TB (P = .02). Basal cell hyperplasia was also found to be more common on TB (P = .02). Both high percentage of stroma (P = .046) and presence of basal cell hyperplasia (P = .038) were independent predictors on multivariate analysis. The combination of high chronic inflammation, high stroma, acute inflammation, and basal cell hyperplasia was associated with TB (P = .001). Atrophic glands and chronic inflammation showed a positive correlation (r = 0.67, P = .003), which was especially seen in high prostate imaging reporting and data system lesions. Specific benign histologic entities are associated with false-positive findings on prostate MRI.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; False-positive imaging; Histology; Multiparametric MRI; Pathology; Prostate biopsy; Prostatitis

Mesh:

Year:  2018        PMID: 30179687      PMCID: PMC8983099          DOI: 10.1016/j.humpath.2018.08.021

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  23 in total

1.  Imaging and pathology findings after an initial negative MRI-US fusion-guided and 12-core extended sextant prostate biopsy session.

Authors:  Cheng William Hong; Annerleim Walton-Diaz; Soroush Rais-Bahrami; Anthony N Hoang; Barış Türkbey; Lambros Stamatakis; Sheng Xu; Hayet Amalou; M Minhaj Siddiqui; Jeffrey W Nix; Srinivas Vourganti; Maria J Merino; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

2.  Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.

Authors:  M Minhaj Siddiqui; Soroush Rais-Bahrami; Baris Turkbey; Arvin K George; Jason Rothwax; Nabeel Shakir; Chinonyerem Okoro; Dima Raskolnikov; Howard L Parnes; W Marston Linehan; Maria J Merino; Richard M Simon; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  JAMA       Date:  2015-01-27       Impact factor: 56.272

Review 3.  Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR.

Authors:  Andrew B Rosenkrantz; Sadhna Verma; Peter Choyke; Steven C Eberhardt; Scott E Eggener; Krishnanath Gaitonde; Masoom A Haider; Daniel J Margolis; Leonard S Marks; Peter Pinto; Geoffrey A Sonn; Samir S Taneja
Journal:  J Urol       Date:  2016-06-16       Impact factor: 7.450

4.  Comparison of systematic transrectal biopsy to transperineal magnetic resonance imaging/ultrasound-fusion biopsy for the diagnosis of prostate cancer.

Authors:  Angelika Borkowetz; Ivan Platzek; Marieta Toma; Michael Laniado; Gustavo Baretton; Michael Froehner; Rainer Koch; Manfred Wirth; Stefan Zastrow
Journal:  BJU Int       Date:  2015-04-27       Impact factor: 5.588

5.  Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions.

Authors:  M Minhaj Siddiqui; Arvin K George; Rachel Rubin; Soroush Rais-Bahrami; Howard L Parnes; Maria J Merino; Richard M Simon; Baris Turkbey; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  J Natl Cancer Inst       Date:  2016-04-29       Impact factor: 13.506

6.  mp-MRI Prostate Characterised PIRADS 3 Lesions are Associated with a Low Risk of Clinically Significant Prostate Cancer - A Retrospective Review of 92 Biopsied PIRADS 3 Lesions.

Authors:  Heath Liddell; Rajeev Jyoti; Hodo Z Haxhimolla
Journal:  Curr Urol       Date:  2015-07-10

7.  Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values.

Authors:  D W Keetch; W J Catalona; D S Smith
Journal:  J Urol       Date:  1994-06       Impact factor: 7.450

8.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.

Authors:  Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton
Journal:  Lancet       Date:  2017-01-20       Impact factor: 79.321

9.  MR Imaging of Pulmonary Nodules: Detection Rate and Accuracy of Size Estimation in Comparison to Computed Tomography.

Authors:  Andrzej Cieszanowski; Antonina Lisowska; Marta Dabrowska; Piotr Korczynski; Malgorzata Zukowska; Ireneusz P Grudzinski; Ryszard Pacho; Olgierd Rowinski; Rafal Krenke
Journal:  PLoS One       Date:  2016-06-03       Impact factor: 3.240

Review 10.  Co-registration of MRI and ultrasound: accuracy of targeting based on radiology-pathology correlation.

Authors:  Win Shun Lai; Jessica G Zarzour; Jennifer B Gordetsky; Soroush Rais-Bahrami
Journal:  Transl Androl Urol       Date:  2017-06
View more
  5 in total

1.  Histopathological Analysis of False-positive Lesions in mpMRI/TRUS Fusion Prostate Biopsy.

Authors:  Ryoken Yamanaka; Yohei Sekino; Takashi Babasaki; Kohei Kobatake; Hiroyuki Kitano; Kenichiro Ikeda; Keisuke Goto; Tetsutaro Hayashi; Jun Teishima; Yukio Takeshima; Yukiko Honda; Kazuo Awai; Nobuyuki Hinata
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

2.  Target prostate biopsies: How best to report in synoptic format?

Authors:  Michelle R Downes; John R Srigley; Andrew Loblaw; Nathan Perlis; Sangeet Ghai; Theodorus van der Kwast
Journal:  Can Urol Assoc J       Date:  2022-04       Impact factor: 1.862

3.  PTEN and ERG detection in multiparametric magnetic resonance imaging/ultrasound fusion targeted prostate biopsy compared to systematic biopsy.

Authors:  Erin Baumgartner; Maria Del Carmen Rodriguez Pena; Marie-Lisa Eich; Kristin K Porter; Jeffrey W Nix; Soroush Rais-Bahrami; Jennifer Gordetsky
Journal:  Hum Pathol       Date:  2019-05-07       Impact factor: 3.466

4.  Comparison of percentage free PSA, MRI and GaPSMA PET scan for diagnosing cancer prostate in men with PSA between 4 and 20 ng/ml.

Authors:  Niraj Kumar; Siddharth Yadav; Sandeep Kumar; Kumar Saurav; Vishnu Prasad; Pawan Vasudeva
Journal:  Indian J Urol       Date:  2019 Jul-Sep

5.  Comparison of Multiparametric Magnetic Resonance Imaging and Gallium-68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Detecting Carcinoma Prostate in Patients with Serum Prostate-Specific Antigen between 4 and 20 ng/ml.

Authors:  Brijesh Kumar Soni; Priyanka Verma; Amit Kumar Shah; Rajendra Singh; Sunita Sonawane; Ramesh V Asopa
Journal:  Indian J Nucl Med       Date:  2021-09-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.